CancerVax Corporation
CancerVax is a pre-clinical biotechnology company dedicated to developing a universal cancer treatment platform that uses the body's immune system to detect, mark, and kill cancer cells. Their innovative approach disguises cancer cells to look like common diseases such as measles, enabling the immune system to target and destroy them. They collaborate with UCLA on multiple research programs, including treatments for Ewing sarcoma and the development of a universal cancer vaccine. The company aims to make cancer treatment as simple as getting a shot, leveraging advanced technologies like AI, nanotechnology, CRISPR, and mRNA.
Industries
Nr. of Employees
small (1-50)
CancerVax Corporation
1633 W Innovation Way, 5th floor, Lehi, UT 84043
Products
Universal cancer treatment platform (mRNA + nanoparticle delivery)
A research-stage, injectable platform that uses engineered mRNA payloads delivered by nanoparticles to induce cancer cells to express distinguishable markers and elicit targeted immune clearance.
Universal in vivo CAR-T platform (nanoparticle-mediated T-cell reprogramming)
A development-stage approach to reprogram a patient’s endogenous T cells in vivo by delivering genetic instructions via nanoparticles to induce CAR expression and redirect T-cell specificity.
Ewing sarcoma bispecific antibody and CAR-T candidates
Preclinical antibody candidates (including fully humanized monoclonal and bispecific formats) and selected CAR constructs targeting a cell-surface biomarker identified on Ewing sarcoma tumors.
Universal cancer treatment platform (mRNA + nanoparticle delivery)
A research-stage, injectable platform that uses engineered mRNA payloads delivered by nanoparticles to induce cancer cells to express distinguishable markers and elicit targeted immune clearance.
Universal in vivo CAR-T platform (nanoparticle-mediated T-cell reprogramming)
A development-stage approach to reprogram a patient’s endogenous T cells in vivo by delivering genetic instructions via nanoparticles to induce CAR expression and redirect T-cell specificity.
Ewing sarcoma bispecific antibody and CAR-T candidates
Preclinical antibody candidates (including fully humanized monoclonal and bispecific formats) and selected CAR constructs targeting a cell-surface biomarker identified on Ewing sarcoma tumors.
Services
Structured sponsored research agreements with university investigators to execute preclinical research programs and obtain exclusive option/license rights to resulting IP.
Management and outsourcing of in vitro and in vivo efficacy studies, flow cytometry, bioanalysis, and mechanistic assays through contract research providers.
Structured sponsored research agreements with university investigators to execute preclinical research programs and obtain exclusive option/license rights to resulting IP.
Management and outsourcing of in vitro and in vivo efficacy studies, flow cytometry, bioanalysis, and mechanistic assays through contract research providers.
Expertise Areas
- Cancer immunotherapy
- mRNA therapeutics
- Nanoparticle/LNP drug delivery
- In vivo CAR-T engineering
Key Technologies
- mRNA therapeutics
- CRISPR gene editing
- Lipid nanoparticles (LNP)
- Nanoparticle delivery systems
News & Updates
The company filed a patent leveraging CRISPR and mRNA technologies to develop a universal cancer treatment that trains the body to target and destroy cancer cells.
The company entered into a sponsored research agreement with UCLA to develop a universal vaccine that detects, marks, and kills cancer cells by forcing them to express unique markers.
The company announced an expansion to develop a universal CAR-T cell platform that can be delivered as a shot to reprogram T-cells inside the body to target cancer.
The company filed a patent leveraging CRISPR and mRNA technologies to develop a universal cancer treatment that trains the body to target and destroy cancer cells.
The company entered into a sponsored research agreement with UCLA to develop a universal vaccine that detects, marks, and kills cancer cells by forcing them to express unique markers.
The company announced an expansion to develop a universal CAR-T cell platform that can be delivered as a shot to reprogram T-cells inside the body to target cancer.